Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.

Alcoholic liver disease Fatty liver Hepatitis B virus Hepatitis C virus Steatohepatitis Steatosis

Journal

Hepatology international
ISSN: 1936-0541
Titre abrégé: Hepatol Int
Pays: United States
ID NLM: 101304009

Informations de publication

Date de publication:
08 Aug 2024
Historique:
received: 31 01 2024
accepted: 03 05 2024
medline: 8 8 2024
pubmed: 8 8 2024
entrez: 8 8 2024
Statut: aheadofprint

Résumé

Metabolic dysfunction-associated fatty liver disease (MAFLD) and viral hepatitis due to chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are common liver diseases worldwide. Excessive alcohol consumption and alcoholic liver disease (ALD) are also emerging health problems. Therefore, in clinical practice, we may encounter subjects with dual etiology of liver diseases such as coexisting MAFLD/HBV, MAFLD/HCV, and MAFLD/ALD. In this review, we summarize the epidemiology, clinical features, and mutual interactions of MAFLD with coexisting HBV, HCV, or ALD. The impact of MAFLD on the progression of liver diseases and treatment outcomes in patients with chronic viral hepatitis and the clinical questions to be addressed regarding dual MAFLD and ALD are also discussed.

Identifiants

DOI: 10.1007/s12072-024-10699-x PMID: 39115632
pubmed: 39115632
doi: 10.1007/s12072-024-10699-x
pii: 10.1007/s12072-024-10699-x
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Science and Technology Council
ID : NSTC 112-2314-B-002-205-MY3
Organisme : Ministry of Education
ID : "Center of Excellence for Metabolic Associated Fatty Liver Disease
Organisme : Ministry of Education
ID : National Sun Yat-sen University
Organisme : Ministry of Education
ID : Kaohsiung" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project

Informations de copyright

© 2024. Asian Pacific Association for the Study of the Liver.

Références

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202–209
pubmed: 32278004 doi: 10.1016/j.jhep.2020.03.039
Liu CJ, Chen PJ. Elimination of hepatitis B in highly endemic settings: lessons learned in Taiwan and challenges ahead. Viruses. 2020;12:815
pubmed: 32731536 pmcid: 7472725 doi: 10.3390/v12080815
Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16:57–73
pubmed: 30158570 doi: 10.1038/s41575-018-0055-0
Vaz K, Clayton-Chubb D, Majeed A, Lubel J, Simmons D, Kemp W, et al. Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes. Hepatol Int. 2023;17:1082–1097
pubmed: 37556065 doi: 10.1007/s12072-023-10568-z
Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862–873
pubmed: 28642059 doi: 10.1016/j.jhep.2017.06.003
Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84
pubmed: 26707365 doi: 10.1002/hep.28431
Yu ML, Chuang WL. Path from the discovery to the elimination of hepatitis C virus: honoring the winners of the nobel prize in physiology or medicine 2020. Kaohsiung J Med Sci. 2021;37:7–11
doi: 10.1002/kjm2.12345
Younossi ZM, Henry L, Janus PO, Tanaka A, Eguchi Y, Mizokami M, et al. Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. Aliment Pharmacol Ther. 2019;49:644–653
pubmed: 30761562 doi: 10.1111/apt.15131
World Health Organization. Global status report on alcohol and health 2018. https://www.who.int/publications/i/item/9789241565639 (2019). Accessed 1 Dec 2023.
Carvalho AF, Heilig M, Perez A, Probst C, Rehm J. Alcohol use disorders. Lancet. 2019;394(10200):781–792
pubmed: 31478502 doi: 10.1016/S0140-6736(19)31775-1
Seto WK. Chronic hepatitis B and metabolic risk factors: a call for rigorous longitudinal studies. World J Gastroentrol. 2019;25:282–286
doi: 10.3748/wjg.v25.i3.282
Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, Chen PJ, et al. Pathologic findings of patients with nonalcoholic fatty liver disease and the impact of concurrent hepatitis B virus infection in Taiwan. J Formos Med Assoc. 2020;119:1476–1482
pubmed: 32499209 doi: 10.1016/j.jfma.2020.05.027
Huang SC, Su HJ, Kao JH, Tseng TC, Yang HC, Su TH, et al. Clinical and histologic features of patients with biopsy-proven metabolic dysfunction-associated fatty liver disease. Gut Liver. 2021;15:451–458
pubmed: 33431715 pmcid: 8129653 doi: 10.5009/gnl20218
Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Combined effects of alcohol and metabolic disorders in patients with chronic liver disease. Clin Gastroenterol Hepatol. 2020;18:995–997
pubmed: 31255807 doi: 10.1016/j.cgh.2019.06.036
Wong VS, Wong GH, Chu WW, et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol. 2012;56:533–540
pubmed: 22027575 doi: 10.1016/j.jhep.2011.09.013
Sakhuja P, Kumar A, Hissar S, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011;54:454–459
pubmed: 21934202 doi: 10.4103/0377-4929.85074
Wang CC, Cheng PN, Kao JH. Systemic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther. 2020;51:216–230
pubmed: 31746482 doi: 10.1111/apt.15575
Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361–1367
pubmed: 21649726 doi: 10.1111/j.1440-1746.2011.06801.x
Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65:828–835
pubmed: 28035771 doi: 10.1002/hep.28917
Wong GL, Chan HL, Yu Z, Chan AW, Choi PC, Chim AM, et al. Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B–a prospective cohort study with paired transient elastography examinations. Aliment Pharmacol Ther. 2014;39:883–893
pubmed: 24612251 doi: 10.1111/apt.12658
Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology. 2017;153:1006–1017
pubmed: 28711626 doi: 10.1053/j.gastro.2017.07.001
Patmore LA, Katwaroe WK, van der Spek D, et al. Association between the presence of metabolic comorbidities and liver-related events in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:3089–3096
pubmed: 37004973 doi: 10.1016/j.cgh.2023.03.024
Huang SC, Su TH, Tseng TC, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17:1139–1149
pubmed: 37247045 doi: 10.1007/s12072-023-10545-6
Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liu CH, et al. Metabolic dysfunction-associated steatotic liver disease facilitates hepatitis B surface antigen seroclearance and seroconversion. Clin Gastroenterol Hepatol. 2023:S1542–3565(23)00842-X.
Ceylan B, Arslan F, Batırel A, Fincancı M, Yardımcı C, Fersan E, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol. 2016;27:42–46
pubmed: 26674977 doi: 10.5152/tjg.2015.150348
Yu JH, Lee JW. How does hepatic steatosis affect the outcome of patients with chronic hepatitis B? Clin Mol Hepatol. 2019;25:280–282
pubmed: 30661335 pmcid: 6759432 doi: 10.3350/cmh.2018.0104
Seto WK, Fung J, Cheung KS, Mak LY, Hui RW, Liu KS, et al. Body-mass index is associated with fibrosis regression during long-term nucleoside analogue therapy in chronic hepatitis B. Aliment Pharmacol Ther. 2016;44:1071–1079
pubmed: 27659292 doi: 10.1111/apt.13804
Zhang Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Aliment Pharmacol Ther. 2021;54:1100–1109
doi: 10.1111/apt.16595
Hu D, Wang H, Wang H, Wang Y, Wan X, Yan W, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int. 2018;12:438–446
pubmed: 29974410 doi: 10.1007/s12072-018-9877-7
Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu Y, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477:2481–2491
pubmed: 33983562 doi: 10.1007/s11010-021-04143-z
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Aliment Pharmacol Ther. 2016;44:877–889
pubmed: 27549244 pmcid: 5113673 doi: 10.1111/apt.13770
Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, et al. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. J Hepatol. 2017;66:1158–1165
pubmed: 28088581 doi: 10.1016/j.jhep.2017.01.003
Xu L, Lu W, Li P, Shen F, Mi YQ, Fan JG. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Dig Liver Dis. 2017;49:910–917
pubmed: 28433586 doi: 10.1016/j.dld.2017.03.013
Liang J, Liu F, Wang F, Han T, Jing L, Ma Z, et al. A noninvasive score model for prediction of NASH in patients with chronic hepatitis B and nonalcoholic fatty liver disease. BioMed Res Int. 2017;2017:8793278
pubmed: 28349067 pmcid: 5352864 doi: 10.1155/2017/8793278
Dong DR, Hao MN, Li C, Peng Z, Liu X, Wang GP, et al. Acoustic radiation force impulse elastography, FibroScan®, Forns’ index and their combination in the assessment of liver fibrosis in patients with chronic hepatitis B, and the impact of inflammatory activity and steatosis on these diagnostic methods. Mol Med Rep. 2015;11:4174–4182
pubmed: 25651500 pmcid: 4394958 doi: 10.3892/mmr.2015.3299
Cho Y, Cho EJ, Yoo JJ, et al. Association between lipid profiles and the incidence of hepatocellular carcinoma: a nationwide population-based study. Cancers (Basel). 2021;13:1599
pubmed: 33808412 doi: 10.3390/cancers13071599
Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667–676
pubmed: 27547913 doi: 10.1111/jgh.13536
Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis. J Viral hepat. 2023;30:793–802
pubmed: 37533208 doi: 10.1111/jvh.13872
Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29:705–720
pubmed: 37157776 pmcid: 10366810 doi: 10.3350/cmh.2023.0004
Mak LY, Hui RW, Lee CH, et al. Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes. Hepatology. 2023;77:606–618
pubmed: 36130882 doi: 10.1002/hep.32716
Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–1243
pubmed: 17531012 doi: 10.1111/j.1572-0241.2007.01181.x
Huang CF, Dai CY, Yeh ML, Huang CI, Lee HC, Lai WT, et al. Cure or curd: modification of lipid profiles and cardio-cerebrovascular events after hepatitis C virus eradication. Kaohsiung J Med Sci. 2020;36:920–928
pubmed: 32643842 doi: 10.1002/kjm2.12275
Attia D, Abdel Alem S, El-Akel W, Abdel-Razek W, Eslam M, Fouad Y, et al. Prevalence and clinical characteristics of patients with metabolic dysfunction-associated fatty liver disease with hepatitis C virus infection-a population-based study. Aliment Pharmacol Ther. 2022;56:1581–1590
pubmed: 36168675 doi: 10.1111/apt.17233
Cheng KL, Wang SW, Cheng YM, Hsieh TH, Wang CC, Kao JH. Prevalence and clinical outcomes in subtypes of metabolic associated fatty liver disease. J Formos Med Assoc. 2024;123:36–44
pubmed: 37491179 doi: 10.1016/j.jfma.2023.07.010
Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586–597
pubmed: 14762795 doi: 10.1053/j.gastro.2003.11.020
Huang CF, Dai CY, Yeh ML, Huang CI, Tai CM, Hsieh MH, et al. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. J Hepatol. 2015;62:512–518
pubmed: 25457210 doi: 10.1016/j.jhep.2014.10.011
Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20
pubmed: 28930295 doi: 10.1038/nrgastro.2017.109
Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol. 2004;38:705–709
pubmed: 15319656 doi: 10.1097/01.mcg.0000135372.10846.2a
Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol. 2005;40:329–336
pubmed: 15868369 doi: 10.1007/s00535-005-1586-z
Lu MY, Huang JF, Liao YC, Bai RK, Trieu RB, Chuang WL, et al. Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Transl Res. 2012;159:58–59
pubmed: 22153811 doi: 10.1016/j.trsl.2011.10.011
Lu MY, Huang CI, Dai CY, Wang SC, Hsieh MY, Hsieh MH, et al. Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. Sci Rep. 2016;6:22995
pubmed: 26965318 pmcid: 4786849 doi: 10.1038/srep22995
Lu MY, Yeh ML, Huang CI, Wang SC, Tsai YS, Tsai PC, et al. Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. World J Gastroenterol. 2022;28:140–153
pubmed: 35125824 pmcid: 8793012 doi: 10.3748/wjg.v28.i1.140
Yu ML, Chen PJ, Dai CY, Hu TH, Huang CF, Huang YH, et al. 2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. J Formos Med Assoc. 2020;119:1019–1040
pubmed: 32359879 doi: 10.1016/j.jfma.2020.04.003
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72:1605–1616
pubmed: 32043613 doi: 10.1002/hep.31173
Wong RJ, Chou C, Sinha SR, Kamal A, Ahmed A. Ethnic disparities in the association of body mass index with the risk of hypertension and diabetes. J Community Health. 2014;39:437–445
pubmed: 24276618 doi: 10.1007/s10900-013-9792-8
Huang JF, Tsai PC, Yeh ML, Huang CF, Huang CI, Lee MH, et al. Community-centered disease severity assessment of metabolic dysfunction-associated fatty liver disease. J Clin Transl Hepatol. 2023;11:1061–1068
pubmed: 37577215 pmcid: 10412709
Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut. 2010;59:1279–1287
pubmed: 20660700 doi: 10.1136/gut.2009.192732
Oliveira C, Fournier C, Descamps V, Morel V, Scipione CA, Romagnuolo R, et al. Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology. 2017;65:1851–1864
pubmed: 28152568 doi: 10.1002/hep.29096
Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA. 1999;96:12766–12771
pubmed: 10535997 pmcid: 23090 doi: 10.1073/pnas.96.22.12766
Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: a reappraisal. J Viral Hepat. 2006;13:73–80
pubmed: 16436124 doi: 10.1111/j.1365-2893.2005.00669.x
Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428–434
pubmed: 11322205 doi: 10.1016/S0168-8278(00)00036-2
Shih CI, Wu KT, Hsieh MH, Yang JF, Chen YY, Tsai WL, et al. Severity of fatty liver is highly correlated with the risk of hypertension and diabetes: a cross-sectional and longitudinal cohort study. Hepatol Int. 2023. https://doi.org/10.1007/s12072-023-10576-z
doi: 10.1007/s12072-023-10576-z pubmed: 37747618
Yeh ML, Yu ML. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: updates of nomenclature and impact on clinical trials. Clin Mol Hepatol. 2023;29:969–972
pubmed: 37718552 pmcid: 10577339 doi: 10.3350/cmh.2023.0359
Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol. 2009;50:712–718
pubmed: 19231011 doi: 10.1016/j.jhep.2008.12.017
Chen CH, Huang JF, Huang CF, Yeh ML, Yang JF, Hsieh MY, et al. Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. Hepatol Int. 2013;7:162–170
pubmed: 26201630 doi: 10.1007/s12072-012-9388-x
Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. Atherosclerosis. 2012;221:496–502
pubmed: 22385985 doi: 10.1016/j.atherosclerosis.2012.01.051
Rout G, Nayak B, Patel AH, Gunjan D, Singh V, Kedia S, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elastography. J Clin Exp Hepatol. 2019;9:207–214
pubmed: 31024203 doi: 10.1016/j.jceh.2018.06.009
Trifan A, Stratina E, Rotaru A, Stafie R, Zenovia S, Nastasa R, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis c infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel). 2022;12:702
pubmed: 35328255 doi: 10.3390/diagnostics12030702
Tokuchi Y, Suda G, Kawagishi N, Ohara M, Kohya R, Sasaki T, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res. 2023;53:595–606
pubmed: 36945790 doi: 10.1111/hepr.13899
Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, et al. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis. 2021;53:1301–1307
pubmed: 33214063 doi: 10.1016/j.dld.2020.11.001
Huang JF, Huang CF, Yeh ML, Dai CY, Hsieh MH, Yang JF, et al. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. Kaohsiung J Med Sci. 2017;33:567–571
pubmed: 29050674 doi: 10.1016/j.kjms.2017.07.003
Adinolfi LE, Nevola R, Guerrera B, D’Alterio G, Marrone A, Giordano M, et al. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33:1379–1382
pubmed: 29228501 doi: 10.1111/jgh.14067
Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, et al. Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut. 2012;61:128–134
pubmed: 21873466 doi: 10.1136/gut.2010.236158
Kawagishi N, Suda G, Nakamura A, Kimura M, Maehara O, Suzuki K, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE. 2018;13: e0209615
pubmed: 30576386 pmcid: 6303061 doi: 10.1371/journal.pone.0209615
Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, et al. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int. 2018;38:1064–1073
pubmed: 29164767 doi: 10.1111/liv.13633
Sano T, Amano K, Ide T, Isoda H, Honma Y, Morita Y, et al. Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: a multicenter study. Hepatol Res. 2023. https://doi.org/10.1111/hepr.13993
doi: 10.1111/hepr.13993 pubmed: 37975277
Pelusi S, Bianco C, Colombo M, Cologni G, Del Poggio P, Pugliese N, et al. Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. Liver Int. 2023;43:1593–1603
pubmed: 37035867 doi: 10.1111/liv.15577
Degasperi E, Galmozzi S, Pelusi R, D’Ambrosio R, Soffredini, Borghi M, et al. Hepatic fat-genetic risk score predicts hepatocellular carcinoma in patients with cirrhotic HCV treated with DAAs. Hepatology. 2020;72:1912–1923
pubmed: 32762045 doi: 10.1002/hep.31500
Fouad Y, Lazarus JV, Negro F, Peck-Radosavljevic M, Sarin SK, Ferenci P, et al. MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. Aliment Pharmacol Ther. 2021;53:1080–1089
pubmed: 33751604 doi: 10.1111/apt.16346
Hirakawa M, Arase Y, Amakawa K, Ohmoto-Sekine Y, Ishihara M, Shiba M, et al. Relationship between alcohol intake and risk factors for metabolic syndrome in men. Intern Med. 2015;54(17):2139–2145
pubmed: 26328637 doi: 10.2169/internalmedicine.54.2736
Kim SK, Hong SH, Chung JH, Cho KB. Association between alcohol consumption and metabolic syndrome in a community-based cohort of Korean adults. Med Sci Monit. 2017;23:2104–2110
pubmed: 28465500 pmcid: 5424649 doi: 10.12659/MSM.901309
Åberg F, Byrne CD, Pirola CJ, Männistö V, Sookoian S. Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease. J Hepatol. 2023;78:191–206
pubmed: 36063967 doi: 10.1016/j.jhep.2022.08.030
Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals. Gut. 2014;63:530–532
pubmed: 24026352 doi: 10.1136/gutjnl-2013-305718
Choi JH, Sohn W, Cho YK. The effect of moderate alcohol drinking in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2020;26:662–669
pubmed: 32971586 pmcid: 7641550 doi: 10.3350/cmh.2020.0163
Mitchell T, Jeffrey GP, de Boer B, MacQuillan G, Garas G, Ching H, et al. Type and pattern of alcohol consumption is associated with liver fibrosis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol. 2018;113:1484–1493
pubmed: 29899440 doi: 10.1038/s41395-018-0133-5
Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, et al. Risks of light and moderate alcohol use in fatty liver disease: follow-up of population cohorts. Hepatology. 2020;71:835–848
pubmed: 31323122 doi: 10.1002/hep.30864
GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the Global burden of disease study 2020. Lancet. 2022;400:185–235
doi: 10.1016/S0140-6736(22)00847-9
Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology. 2019;69:64–75
pubmed: 30019340 doi: 10.1002/hep.30170
Díaz LA, Arab JP, Louvet A, Bataller R, Arrese M. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20:764–783
pubmed: 37582985 doi: 10.1038/s41575-023-00822-y
Romeo S, Sanyal A, Valenti L. Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab. 2020;31:35–45
pubmed: 31914377 doi: 10.1016/j.cmet.2019.12.002
Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet. 2010;42:21–23
pubmed: 19946271 doi: 10.1038/ng.488
Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30:675-688.e7
pubmed: 31543403 doi: 10.1016/j.cmet.2019.08.018
Gan L, Feng Y, Du B, Fu H, Tian Z, Xue G, et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae. Nat Commun. 2023;14:3215
pubmed: 37270557 pmcid: 10239455 doi: 10.1038/s41467-023-39028-w
Hahn JA, Fatch R, Barnett NP, Marcus GM. Phosphatidylethanol vs transdermal alcohol monitoring for detecting alcohol consumption among adults. JAMA Netw Open. 2023;6: e2333182
pubmed: 37698861 pmcid: 10498325 doi: 10.1001/jamanetworkopen.2023.33182
Åberg F, Luukkonen PK, But A, Salomaa V, Britton A, Petersen KM, et al. Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score. J Hepatol. 2022;77:302–311
pubmed: 35271949 doi: 10.1016/j.jhep.2022.02.021
Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14:889–919
pubmed: 33006093 doi: 10.1007/s12072-020-10094-2
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797–1835
pubmed: 36727674 doi: 10.1097/HEP.0000000000000323
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, et al. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. J Hepatol. 2021;74:1188–1199
pubmed: 33278455 doi: 10.1016/j.jhep.2020.11.045

Auteurs

Chun-Jen Liu (CJ)

Hepatitis Research Center, National Taiwan University College of Medicine and, National Taiwan University Hospital, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.

Wai Kay Seto (WK)

Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Pok Fu Lam, China. wkseto@hku.hk.

Ming-Lung Yu (ML)

Hepatobiliary Division, Department of Internal Medicine, Center of Hepatitis Research, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. fish6069@gmail.com.
School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-Sen University, Kaohsiung, Taiwan. fish6069@gmail.com.
ORCID: 0000-0001-8145-1900

Classifications MeSH